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AbstrACt
Objective To estimate the costs and outcomes associated 
with treating non- asthmatic adults (nor suffering from 
other lung- disease) presenting to primary care with 
acute lower respiratory tract infection (ALRTI) with oral 
corticosteroids compared with placebo.
Design Cost- consequence analysis alongside a 
randomised controlled trial. Perspectives included the 
healthcare provider, patients and productivity losses 
associated with time off work.
setting Fifty- four National Health Service (NHS) general 
practices in England.
Participants 398 adults attending NHS primary practices 
with ALRTI but no asthma or other chronic lung disease, 
followed up for 28 days.
Interventions 2× 20 mg oral prednisolone per day for 
5 days versus matching placebo tablets.
Outcome measures Quality- adjusted life years using the 
5- level EuroQol- 5D version measured weekly; duration and 
severity of symptom. Direct and indirect resources related 
to the disease and its treatment were also collected. 
Outcomes were measured for the 28- day follow- up.
results 198 (50%) patients received the intervention 
(prednisolone) and 200 (50%) received placebo. NHS costs 
were dominated by primary care contacts, higher with 
placebo than with prednisolone (£13.11 vs £10.38) but 
without evidence of a difference (95% CI £3.05 to £8.52). 
The trial medication cost of £1.96 per patient would have 
been recouped in prescription charges of £4.30 per patient 
overall (55% participants would have paid £7.85), giving 
an overall mean ‘profit’ to the NHS of £7.00 (95% CI £0.50 
to £17.08) per patient. There was a quality adjusted life 
years gain of 0.03 (95% CI 0.01 to 0.05) equating to half a 
day of perfect health favouring the prednisolone patients; 
there was no difference in duration of cough or severity of 
symptoms.
Conclusions The use of prednisolone for non- asthmatic 
adults with ALRTI, provided small gains in quality of 
life and cost savings driven by prescription charges. 
Considering the results of the economic evaluation and 
possible side effects of corticosteroids, the short- term 
benefits may not outweigh the long- term harms.
trial registration numbers EudraCT 2012-000851-15 
and ISRCTN57309858; Pre- results.
IntrODuCtIOn
Acute lower respiratory tract infection 
(ALRTI), with symptoms such as wheeze, 
phlegm and chest pain, is one of the most 
common reasons for patients to consult 
in primary care.1 In the UK, ALRTI costs 
the National Health Service (NHS) at least 
£190 million annually,2 and further costs 
are borne by patients in self- managing their 
condition3 4 and by society in general because 
of work absenteeism.5
Despite lack of evidence of efficacy and 
the recommendation from the National 
Institute for Health and Care Excellence of 
a non- antibiotic pathway,6 antibiotics are still 
strengths and limitations of this study
 ► The economic evaluation was part of a rigorously 
conducted multicentre randomised controlled trial, 
involving a representative population of patients not 
thought to need immediate antibiotic treatment.
 ► The economic evaluation included the perspectives 
of patients and time off work as well as the National 
Health Service.
 ► Low levels of missing cost and outcome data, with 
EuroQol 5D observations from multiple time points, 
achieving an accurate profile of patient health- 
related quality of life over the period of the illness.
 ► The analysis was thorough and included multiple 
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frequently prescribed to treat ALRTI.7 8 This unnecessary 
prescribing fuels antimicrobial resistance, raises patient 
expectations for similar treatment in the future (so- called 
‘illness medicalisation’) and is a wasteful use of health-
care resources.
Oral and inhaled corticosteroids are widely used to 
treat symptoms of asthma9 and there is some evidence of 
the effectiveness of high doses of inhaled corticosteroids 
in reducing cough frequency among non- smokers with 
ALRTI who do not have asthma or other chronic lung 
disease.10 Given the similarity in symptoms of ALRTI and 
those of asthma, we tested the hypothesis that corticoste-
roids might be an effective treatment for ALRTI in adults 
without asthma or other chronic lung disease. Indeed, 
there is increasing evidence from Europe11 and the 
USA12 of steroid prescribing for patients with ALRTI, with 
a secondary analysis of one US study12 showing 15% of 
adults without asthma but with ALRTI being prescribed 
oral steroids.
The Oral Steroids for Acute Cough (OSAC) study13 14 
examined the effectiveness and costs of oral corticoste-
roids (more specifically oral prednisolone) in treating 
ALRTI in a non- asthmatic adult population compared 
with placebo. Here, we report on the results of the 
economic evaluation.
MethODs
The OSAC study was a two- arm randomised controlled 
trial that aimed to test the provision of oral corticosteroids 
to adults with ALRTI but no asthma or other chronic lung 
disease such as chronic obstructive pulmonary disease. 
Details of the trial procedures and clinical results are 
reported elsewhere.13 14 Briefly, patients with an ALRTI- 
related cough were recruited from 54 primary care prac-
tices across four areas of England and randomly allocated 
to receive either oral prednisolone (intervention) or 
placebo (control) for their acute cough symptoms. The 
intervention consisted of 40 mg (two 20 mg tablets) of 
prednisolone daily for 5 days. The control group received 
matching placebo tablets. The primary clinical outcomes 
of the study were duration of ‘moderately bad or worse’ 
cough and symptom severity for days 2 to 4 postrandomis-
ation. The primary outcome for the economic evaluation 
was quality adjusted life years (QALYs) which were esti-
mated from responses to the 5- level EuroQol- 5D version 
(EQ- 5D- 5L).15
Design
The economic evaluation was conducted from the 
perspectives of the NHS, patients and a broader perspec-
tive taking into account differences in work- related 
productivity costs; we included all resource use during 
the 28- day follow- up period. We used a cost- consequences 
design,16 comparing cost from the three perspectives with 
the clinical outcomes and QALYs to see all possible costs 
and health consequences.
Identification of resources
NHS resources were identified as being: the trial medi-
cation, primary care consultations, other relevant 
prescribed medication, hospital care, use of NHS 111 and 
ALRTI- related investigations such as chest X- ray. Patient 
resource use was identified as being: travel, prescription 
costs and over- the- counter medication and remedies. 
Productivity losses were identified as being days off work 
due to the cough.
Measurement of resources: data collection
A primary care notes review took place at the end of the 
study period, and data were extracted on: all primary care 
consultations, categorised as doctor or nurse, face to face, 
telephone or home visit and in- hours or out- of- hours; 
prescribed medication and investigations. Participants in 
the study were issued with a daily diary to complete, which 
was used to collect data on health service use not always 
reliably available from primary care notes such as use of 
NHS 111 and hospital services. Participant out- of- pocket 
expenses on travel and over- the- counter medicines were 
also recorded here, along with time off work. Partici-
pants were telephoned weekly to reinforce their record 
keeping.
Valuation of resources
Resources were valued as shown in table 1. All resources 
were costed in pounds sterling at 2013–2014 prices, using 
an appropriate inflation index17 when necessary. Costs for 
primary care services were obtained from Curtis17; calls 
to the NHS 111 service were costed using a published 
national evaluation,18 and NHS reference costs19 were 
used to value secondary care services. Travelling by car was 
valued using the Automobile Association (AA) running 
schedule to cost the mileage,20 and standard ticket prices 
were employed to cost the use of public transport. Produc-
tivity costs were derived using the age/sex average rate 
from the Annual Survey of Hours and Earnings.21
For prescribed medication, costs were extracted mainly 
from the British National Formulary (BNF).22 A cost was 
obtained for each prescription based on the name of the 
drug, the method of administration (for example, tablet, 
capsule, liquid) and the number of units included in the 
prescription. When the cost of a drug was not available 
in the BNF, the Prescription Costs Analysis of England 
database23 was used to cost that medication. Uncertainties 
around relevance (to ALRTI) and missing information 
were resolved by seeking clinical advice.
Careful consideration was given to the most accurate 
way of costing the intervention medication (predniso-
lone) with the aim of reflecting the true cost to the NHS 
if it were to be adopted as a strategy for treating ALRTI. 
First, thought was given to the number of pills that would 
be needed to cover the intervention total dose as the 
20 mg tablets provided in the study are not routinely 
available. We assumed that 5 mg tablets would be a 
reasonable substitute, resulting in 8 tablets required per 
day, and 40 tablets for the duration of the intervention 
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  GP (face to face in practice) 46.00*
  GP (telephone call) 28.00*
  GP (out of hours) 68.30*
  Practice nurse (face to face in practice) 13.69*
  Practice nurse (telephone call) 9.00*
  Nurse practitioner(face to face in 
practice)
25.00*
  Nurse practitioner (out of hours) 33.41*
  NHS 111 calls 8.29†
Hospital and walk- in services
  Walk- in centre 40.50‡
  Outpatient 150.00/214.00§¶
  A&E visits 111.20‡
  Investigations (X- ray) 28.01‡
Medication
  Prescribed medication By item§**
  Prednisolone (intervention) 1.96§**
  Over- the- counter medication By item
  Prescription charge 7.85
Other
  Mileage 0.64††





¶£214.00 was used for a patient who had a very resource- 
intensive outpatient stay (upper bound outpatient cost).
**Prescription Pricing Authority.23
††AA schedule.20
‡‡Office of National Statistics.21
A&E, accident and emergency; BNF, British National Formulary; 
GP, general practitioner; NHS, National Health Service.
(5 days). From the basic price of £1.03 given in the BNF, 
adjustments were made as follows. We subtracted the 
usual discount (7.61% of the basic price) eligible to the 
dispensing pharmacy from the manufacturer; we added 
a standard 90 p dispensing fee and a payment of 1.24 p 
for consumables; and as the amount required was 40 
and packs contain 28 tablets, an extra 10 p for splitting 
packs was added. This resulted in a cost for the interven-
tion prednisolone of £1.96. To reflect a ‘roll- out’ situa-
tion, we allowed for potential receipts from prescription 
payments made by patients by including an amount for 
those participants who reported that they usually pay a 
prescription charge.
No cost was included for the placebo medication (ie, 
tablets) as this was a research cost.
Measurement and valuation of outcomes
The EQ- 5D- 5L was completed weekly by participants from 
baseline during the 28- day follow- up, giving us five obser-
vations to use to form QALYs. Utilities were obtained from 
existing preferences elicited from the general public, 
using the cross- walk algorithm.15 QALYs were calculated 
from these utilities using the area under the curve and 
adjusting for baseline differences.24
Results from the clinical trial14 show that the median 
duration of moderately bad or worse cough was 5 days 
in both groups and the HR of 1.11 (95% CI 0.89 to 1.39) 
also indicates no difference. There was a reduction of 
0.02 in mean symptom score for days 2 to 4 in predniso-
lone patients though this was less than the predetermined 
clinically meaningful difference.
Data analysis
Frequencies of resource use were calculated to provide 
a descriptive analysis of the types of resources used by 
primary care patients with a cough. We estimated mean 
resource use and cost per patient for all categories, by 
trial arm, to compare the prednisolone group with 
those using the placebo. Ordinary least squares regres-
sions were employed to calculate the differences in costs 
adjusted for centre, age, gender and outcome- related 
baseline variables to account for potential imbalances 
between the groups. Standard deviations (for means) and 
bias- corrected bootstrapped CIs25 (2000 replicates) were 
constructed to account for the uncertainty in the point 
estimates.
No discount was applied to the data as the time horizon 
of the study was 28 days. All analyses were carried out 
using Stata V.13 and above.26
sensitivity analyses
Five different sensitivity analyses were conducted to test 
the robustness of assumptions made in the base case 
analysis. The effect of missing data was appraised in two 
scenarios using multiple imputation techniques: in addi-
tion to the imputation with chained equations (ICE) 
(scenario 1), which is usually employed in economic eval-
uations, an analysis was also carried out using the ‘twofold’ 
command in Stata; this command imputes missing values 
at a given time point, conditional on information at the 
same time point and immediately adjacent time points27 
(scenario 2), to be consistent with the methodology used 
in the clinical effectiveness analysis.14 Scenario 3 excluded 
outpatient and accident and emergency attendances 
where there was any ambiguity about their relevance to 
LRTI; scenario 4 used the visual analogue scale to calcu-
late QALYs; and scenario 5 removed the prescription 
payments from the analysis on the basis that these are to 
some extent artefactual and relate specifically to England 
at the time of the study.
Patient and public involvement
Patient participation and involvement (PPI) input was 
important in the decision to prioritise the research 
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Table 2 Mean (SD) resource use, per patient, by category and group (all available data)
Resource use category
Prednisolone Placebo Unadjusted difference
n Mean (SD) n Mean (SD) Mean (95% CI)
Primary care consultations 195 0.27 (0.58) 198 0.30 (0.73) −0.03 (−0.16 to 0.10)
Prescribed medication 190 0.15 (0.51) 200 0.22 (0.64) −0.06 (−0.18 to 0.05)
NHS 111 calls 177 0.04 (0.22) 168 0.02 (0.13) 0.02 (−0.02 to 0.06)
X- ray procedures 197 0.04 (0.19) 198 0.04 (0.20) 0.00 (−0.04 to 0.03)
All hospital visits 176 0.02 (0.13) 166 0.04 (0.23) −0.03 (−0.06 to 0.01)
Trial medication 198 1 (0) 200 0 (0) 1 (1 to 1)
Prescription payments 191 0.62 (0.66) 181 0.09 (0.39) 0.52 (0.41 to 0.64)
Over the counter medication 180 0.48 (0.67) 168 0.59 (0.83) −0.11 (−0.26 to 0.05)
Time off work (days) 171 0.95 (2.61) 165 1.38 (3.05) −0.43 (−1.04 to 0.18)
NHS, National Health Service.
question for funding, and their views informed discus-
sions around the design of the study, the sample size calcu-
lation and selection of primary and secondary outcomes. 
PPI views were sought on recruitment methods, and all 
patient facing trial materials. The burden of the interven-
tion was also assessed by patients themselves, and results 
were disseminated to both practices and the patients. We 
wish to thank our PPI advisors for their input into trial 
design and management.
results
In total, 398 patients were included in the intention- to- 
treat analysis. One hundred and ninety- eight (49.7%) 
were in the trial medication (intervention) group and 
200 (50.3%) received the matched placebo (control). 
Baseline characteristics of the participants are shown 
in online supplementary appendix table A. Participants 
were predominantly white, employed and middle aged 
and similar rates received asthma medication in both 
groups (5% vs 4%) during the previous years. Approxi-
mately 50% in both arms stated they had never smoked. 
Data on NHS costs were complete for 332 (83%) partici-
pants and out- of- pocket costs for patients were reported 
by 329 (83%). Time off work was recorded by 321 (81%) 
of the participants filling the questionnaire and 346 
(87%) completed the EQ- 5D- 5L at all five time points.
resource use
Use of all health services was relatively modest during the 
28- day follow- up period. Overall just 20% participants 
accessed primary care, a proportion that was similar for 
both groups though patients in the placebo group had 
slightly more consultations per patient than those in the 
prednisolone group, which is reflected in the mean number 
of encounters (0.30 vs 0.27) as shown in table 2. Prescribed 
medication was also slightly higher in the placebo group in 
terms of number of patients (15% vs 12%) being prescribed 
anything and the mean number of prescriptions per partici-
pant (0.22 vs 0.15). Nine participants (2%) reported using 
hospital services: three (1.5%) in the prednisolone group 
and six (3%) in the placebo group.
More placebo group participants reported buying over- 
the- counter medications than those in the prednisolone 
group (45% vs 39%), and the mean number of items 
per participant was higher (0.59 vs 0.48). Popular items 
included cough linctus and cold and influenza remedies. 
Similarly, more placebo group participants reported time 
off work than prednisolone participants (32% vs 28%), and 
the mean length of time off was longer (1.38 days vs 0.95 
days).
Although there was a consistently higher use of resources 
in the placebo group compared with the prednisolone 
group, there is imprecision around the point estimates and, 
with the exception of the trial medication and associated 
prescription payments, there is no evidence of a difference 
in use between the groups as indicated by the CIs reported 
in table 2.
Cost analysis
Table 3 summarises the cost comparison between the two 
groups. The majority of NHS costs were attributable to 
primary care consultations with hospital visits, including for 
X- rays, contributing a modest amount. Over half (55%) of 
prednisolone participants reported that they normally pay 
a prescription charge; the value of prescription payments 
made by these patients more than covered the cost of the 
trial medication meaning that the NHS on balance would 
have made a profit. Out- of- pocket patient costs were domi-
nated by prescription payments and the value of time off 
work was higher than any other category of cost. Comparing 
the prednisolone and placebo groups, costs were higher in 
the placebo group for all categories (except those related to 
the trial medication) though again there was no evidence 
of a difference between the groups as indicated by the CIs.
Cost-consequence analysis
Table 4 shows the comparison of incremental costs and 
outcomes, including the results from the clinical trial 
regarding duration of cough and symptom severity score. 
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Table 3 Mean (SD) cost (£) by group, per patient, by category and group (all available data)
Resource use category
Prednisolone Placebo Unadjusted difference
n Mean (SD) n Mean (SD) Mean (95% CI)
Primary care consultations 195 10.38 (23.97) 198 13.11 (33.52) −2.73 (−8.52 to 3.05)
Prescribed medication 195 0.36 (1.27) 194 0.44 (1.33) −0.08 (−0.34 to 0.17)
NHS 111 calls 168 0.33 (1.85) 177 0.33 (1.85) 0.18 (−0.14 to 0.50)
X- ray procedures 198 1.00 (5.20) 197 1.00 (5.20) −0.14 (−1.20 to 0.93)
All hospital visits 176 1.09 (9.39) 166 3.84 (23.10) −2.75 (−6.46 to 0.97)
Trial medication 198 1.96 (0) 200 0 (0) 1.96 (1.96 to 1.96)
Prescription payments* 191 4.85 (5.20) 181 0.74 (3.06) 4.11 (3.24 to 4.99)
Over the counter medication 175 2.23 (3.93) 165 3.08 (5.07) −0.85 (−1.82 to 0.11)
Travel costs 171 1.76 (2.63) 166 2.45 (4.39) −0.69 (−1.47 to 0.08)
Time off work (days) 161 58.02 (161.16) 160 83.88 (183.93) −25.86 (−63.83 to 12.11)
*Prescription payments are a transfer cost between the NHS and patients. They are a negative cost (receipt) to the NHS and a positive cost to 
patients.
NHS, National Health Service.
Table 4 Cost- consequence analysis. Differences in mean 
(95% CI) cost and QALY (complete cases, by perspective)
Mean (95% CI)* difference
All NHS services (n=332) −£7.00 (−£17.08 to −£0.50)
All patient out- of- pocket 
expenditure (n=329)
£2.90 (£1.14 to £4.48)
Value of time off work (n=321) −£30.45 (−£ 67.15 to £9.79)
QALYs (n=346) 0.03 (0.01 to 0.05)
Duration of cough (n=334) HR: 1.11 (0.89 to 1.39)
Symptom severity score (n=368) −0.20 (−0.40 to 0.00)
* Biased corrected and adjusted by centre and baseline 
covariates.
NHS, National Health Service; QALYs, quality adjusted life years.
Here, we present the difference in cost by perspective, 
adjusted by centre, age, gender and baseline covariates. 
The 95% CIs are bootstrapped and bias corrected. The 
negative incremental cost of −£7.00 (95% CI −£17.08 to 
−£0.50) per patient to the NHS indicates the interven-
tion is cheaper than placebo; it reflects the lower use of 
primary care by patients in the prednisolone group and 
the offset of intervention costs by prescription payments. 
From the patient perspective, despite higher travel and 
over- the- counter costs in the placebo group, total costs 
were approximately £3 more in the prednisolone group 
due to the cost of prescriptions. The value of time off 
work was approximately £30 higher per patient for the 
placebo group.
The gain in quality of life provided by the prednisolone 
was 0.03 QALYs (95% CI 0.01 to 0.05) per patient, which 
translates into slightly more than half a day of extra ‘best 
imaginable’ health during the 28 days. The percentage 
of patients reporting no problems for each domain of 
the EQ- 5D are shown in online supplementary appendix 
table B. On average, the prednisolone patients improved 
by more than the placebo patients in all domains, but the 
‘pain and discomfort’ and ‘usual activities’ domains were 
where the greatest difference was seen.
sensitivity analysis
Results of the sensitivity analyses are presented in table 5. 
Imputing missing data and excluding unrelated costs 
make no difference to the conclusions of the base case 
analysis. Using the visual analogue scale to value the 
QALYs reduced the QALY gain of prednisolone patients 
over placebo to a minimal amount (0.01: 95% CI −0.01 
to 0.03). When prescription payments are removed, the 
incremental cost to the NHS is still negative (−£3.04; 
95% CI −£11.31 to £5.24) though the CI suggests no 
evidence of a true difference. The reverse is true for 
patient costs as placebo patients spent considerable more 
on travel and over- the- counter medications and remedies 
than those in the prednisolone group.
DIsCussIOn
summary of main findings
Prednisolone was found to be clinically ineffective for 
treating ALRTI in non- asthmatic adults in primary care in 
terms of duration of cough and symptom severity14 ; however 
there was evidence that patients using prednisolone expe-
rienced a greater improvement in health- related quality of 
life than those using the placebo. This was largely due to 
a greater improvement in pain/discomfort and a speedier 
return to carrying out usual activities. Prednisolone is a 
relatively inexpensive medication and, in this population of 
generally healthy adults ineligible for prescription charge 
exemption, prescription payments more than offset the 
cost to the NHS. Other NHS resource use was consistently 
higher in the placebo group across all categories though 
the differences were small. The value of time off work was 
considerable, and this was higher in the placebo patients, 
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1. Imputed data (ICE)
NHS services −£9.78 (−£19.05 to −£3.87)
Patient out- of- pocket 
expenditure
£3.01 (£1.06 to £4.28)
Value of time off work −£22.99 (−£55.81 to £12.97)
QALYs 0.03 (0.01 to 0.04)
2. Imputed data (twofold)
NHS services −£7.27 (−£17.12 to −£0.91)
Patient out- of- pocket 
expenditure
£2.97 (£1.16 to £4.54)
Value of time off work −£28.36 (−£67.75 to £9.38)
QALYs 0.03 (0.01 to 0.04)
3. Exclusion of potentially unrelated cost categories (n=332)
NHS services −£6.20 (−£13.77 to £0.14)
4. QALYs using VAS (n=326)
QALYs 0.01 (−0.01 to 0.03)
5. Removal of prescription payments (n=334)
NHS services −£3.04 (−£11.31 to £5.24)
Patient out- of- pocket 
expenditure
−£1.49 (−£2.83 to −£0.16)
*Adjusted by centre and baseline covariates.
NHS, National Health Service; QALYs, quality adjusted life years; 
VAS, visual analogue scale.
though the limited sample size combined with patient- level 
variation prevented a robust conclusion.
strengths and weaknesses
The sample included in OSAC was typical of patients 
consulting in primary care with ALRTI, not thought to 
require immediate antibiotic treatment. The two groups 
were well matched at baseline and there was minimal 
drop- out. The economic evaluation was carried out at indi-
vidual patient level and covered the whole 28- day period. 
Data on actual utility values for each group was not reported, 
which would have helped to understand the differences 
regarding quality of life data between each group; however, 
the weekly collection of EQ- 5D- 5L data allowed for an accu-
rate estimate of the recovery profile of patients, capturing 
the speedier improvement of those in the prednisolone 
group, suggesting that they ‘felt better’ more quickly than 
those taking the placebo. In this trial, there were low levels 
of missing data; however, when estimating cost at a number 
of time points over the whole trial period, any missing 
resource use data pose a threat. From the NHS perspec-
tive, there were 332 complete cases representing 83% of 
the total sample who provided data at all time points. The 
total amount of missing data points was less than this which 
is borne out by the results of the multiple imputation, 
confirming that the complete cases estimates are robust. 
The size of the sample for the trial was based on the primary 
clinical outcomes, as is common practice. Patient variability 
affected the uncertainty around the estimates of mean cost, 
so although there were suggestions of differences between 
the groups (especially for time off work), the sample was 
not large enough for this to be confirmed beyond chance. 
The economic evaluation was restricted by the procedures 
and time frame of the trial. We did not include a cost for the 
placebo medication, but it is possible that in a ‘real- life’ situ-
ation, an alternative treatment such as a codeine linctus, an 
inhaler or an oral antibiotic might be prescribed. Although 
it was appropriate to limit the follow- up period to 28 days to 
answer the clinical question, we were unable to capture any 
long- term effects of either repeated use of corticosteroids, 
such as illness medicalisation or osteoporosis,28 or a reduc-
tion in repeated days off work.
Comparison with other literature (strengths and weaknesses)
We are aware of no other studies investigating the clinical 
and economic implications of corticosteroids for ALRTI. 
However, our estimates of cost and quality of life can be 
compared separately with other literature. Oppong et al29 
conducted a thorough analysis of resource use and cost for 
acute cough/LRTI in 13 European countries. The use of 
primary healthcare services in that study was slightly higher 
than our figure of 0.28 per participant: they found a mean 
of 0.34 visits for the two UK centres included in the study 
and an overall range of 0.30 to 1.89. However, this differ-
ence is small and may be accounted for by different inclu-
sion criteria. On the other hand, the amount of time off 
work was considerably different. Our participants reported 
a mean length of 1.16 days off work compared with 3.08 
in the European study, though it is difficult to tell whether 
those authors included a value (representing ‘potential’ 
time off) for participants not in paid work. Only one- third 
of our participants reported any time off work, but for those 
who did, the mean length was 3.9 days. In this study, we 
found a small but significant improvement in quality of 
life for patients taking prednisolone compared with those 
taking the placebo. In a recent review of short course oral 
steroids for chronic rhinosinusitis,30 an improvement in 
quality of life was observed at the end of a 2–3- week course 
though the quality of this evidence was judged to be low. 
There is also some evidence of patients reporting positive 
mood change when taking steroids.31
Meaning of the study/policy implications
The results of this study pose an interesting challenge in 
terms of interpretation. Despite the negative clinical (cough 
duration and symptom severity) endpoint results, we found 
prednisolone was cheaper (in terms of NHS costs) than 
placebo and better (in terms of QALY gain), but each of 
these findings comes with a caveat. Once the benefit of 
prescription payments was removed from the analysis the 
cost gain was much reduced, and could have been due to 
chance. Placebo patients consistently used more healthcare 
services than those on prednisolone, but as the trial was not 
powered to detect a difference in cost, we cannot draw any 
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firm conclusions. Although the short- term use of prednis-
olone may make patients feel a little better, the negative 
effects of longer term or repeated use, such as illness medi-
calisation32 and osteoporosis28 cannot be accounted for in 
this analysis and are potentially powerful arguments against 
more widespread use.
The results of this study evidence a small increment of 
the quality of life—particularly in pain/discomfort and 
resumption of usual activities—in patients who take pred-
nisolone to treat their ALRTI symptoms. However, taking 
the clinical and economic implications derived from this 
study, and considering the possibility of side- effects from 
repeated short- term use, the benefits may not outweigh 
the unknown long- term risk.
unanswered questions and future research
This study has addressed the question of the short- term use 
of corticosteroids for ALRTI, but more work is needed to 
understand the longer term influences. One motivation for 
carrying out the research was concern about inappropriate 
prescribing of antibiotics for conditions such as ALRTI, 
particularly with respect to the effect on antimicrobial resis-
tance. Corticosteroids are successfully used in the short term 
for many conditions and the long- term detrimental effects, 
such as osteoporosis, high blood pressure and suppression 
of the immune system are recognised; a recent study33 
showed that adverse events can develop within 1 month 
of short- term steroid use in patients with acute respiratory 
tract infections; however, the specific long- term effect of 
repeated short- term use of steroids by ALRTI patients is 
uncertain. Future work could include long- term modelling 
of the costs and effects of alternative treatments for ALRTI, 
including corticosteroids, antibiotics and other medications 
with little or marginal effect such as linctus. The modelling 
could take a broad perspective, including the impact of lost 
productivity, and address the challenge of weighing up the 
societal cost of antimicrobial resistance against patient level 
side- effects of medication and the potential for overmed-
icalisation of ALRTI. In some studies,2 34 the small gains 
in time to recovery provided by antibiotics (12–24 hours) 
was not sufficient to outweigh their risks. Our study did not 
measure this variable; however, future research would be 
necessary to ascertain whether a similar conclusion could 
be obtained for prednisolone.
COnClusIOn
The economic evaluation evidences gains in quality of life 
provided by the use of prednisolone for non- asthmatic 
adults with ALRTI from the perspective of the NHS. 
However, the benefit is small and taking the clinical and 
economic implications derived from this study and consid-
ering the potential side effects from repeated use of corti-
costeroids, the short- term benefits may not outweigh the 
long- term harms.
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